Cargando…
Treatment of Membranous Nephropathy by Disulfiram through Inhibition of Podocyte Pyroptosis
INTRODUCTION: Membranous nephropathy (MN) is a common chronic kidney disease in adults and a major challenge of clinical practice for its treatment. Despite major advances, since the discovery of the phospholipase A2 receptor as the major autoantigen of podocytes in MN, the mechanisms leading to glo...
Autores principales: | Lv, Daoyuan, Jiang, Song, Zhang, Mingchao, Zhu, Xiaodong, Yang, Fan, Wang, Hui, Li, Shen, Liu, Feng, Zeng, Caihong, Qin, Weisong, Li, Limin, Liu, Zhihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386405/ https://www.ncbi.nlm.nih.gov/pubmed/36157258 http://dx.doi.org/10.1159/000524164 |
Ejemplares similares
-
Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction
por: Wang, Hui, et al.
Publicado: (2022) -
Upregulated LRRC55 promotes BK channel activation and aggravates cell injury in podocytes
por: Hu, Shuai, et al.
Publicado: (2020) -
HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy
por: Wen, Jiqiu, et al.
Publicado: (2016) -
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
por: Hu, Jun Jacob, et al.
Publicado: (2020) -
Disulfiram alleviates pristane-induced lupus via inhibiting GSDMD-mediated pyroptosis
por: Zhuang, Lili, et al.
Publicado: (2022)